Novoteris, LLC., Medical Device and Pharmaceutical Product Innovators, Receives Orphan Drug Designation for Nitric Oxide for the Treatment of Cystic Fibrosis Application Brings Years of Work with Nitric Oxide Gas for Antimicrobial Use to Clinical Fruition

GARDEN GROVE, Calif., Oct. 9, 2013 /PRNewswire/ -- Novoteris, LLC., a clinical stage medical device and pharmaceutical developer focused on innovative applications for nitric oxide gas where it can be applied for unmet medical needs, announced today that the Office of Orphan Products Development of the US Food and Drug Administration has granted it orphan drug designation for the use of inhaled nitric oxide for the treatment of Cystic Fibrosis. 

(Logo: http://photos.prnewswire.com/prnh/20131009/PH94251LOGO)

The US Orphan Drug Act is intended to encourage companies to develop safe and effective therapies for the treatment of rare diseases and disorders.  In addition to providing a seven year term of market exclusivity upon final FDA approval, orphan drug designation also positions Novoteris to be able to leverage a wide range of financial and regulatory benefits, including government and institutional grants, and waiver of FDA user fees for the potential submission of a New Drug Application.

"The FDA's decision to grant nitric oxide orphan drug designation for this indication signifies an important step for Novoteris," stated Alex Stenzler, President of Novoteris.  "The marketing exclusivity that orphan drug designation imparts adds significantly to the existing patent estate acquired by Novoteris." Chris Miller, PhD, Chief Science Advisor, noted that, "The results from our pilot trial demonstrated more than a 15% increase in lung function following two weeks of therapy and we anticipate that we will be able to demonstrate similar outcomes in our Phase II trials." Following the presentation of the data from the pilot trial, both the US Cystic Fibrosis Foundation and the European Cystic Fibrosis Society sent letters of support for the Orphan Drug designation.

About Cystic Fibrosis

Cystic fibrosis (CF) is an autosomal recessive genetic disorder that affects most critically the lungs. Difficulty breathing is the most serious symptom and results from frequent lung infections that are most often treated with lifelong inhaled antibiotics.  Development of drug resistance to available antibiotics is a major concern for patients with CF.

About Nitric Oxide

Nitric oxide, an endogenous molecule, is the most important signaling molecule in the body and plays an important role in every organ system, including the innate defense system against microorganisms. Exogenous nitric oxide has been demonstrated to be an effective antimicrobial agent against a broad spectrum of microbes, including drug resistant strains.  A lower concentration of nitric oxide is already on the market from other manufacturers for the treatment of pulmonary hypertension in newborns.  "This new application brings years of work with nitric oxide gas for antimicrobial uses to the clinical forefront," added Dr. Miller.

About Novoteris, LLC.

Novoteris is a privately held limited liabilities corporation that is managed by a group of international industry veterans and clinicians involved in developing and producing innovative, cutting-edge medical products.

Contact Information: 

Alex Stenzler,

President

Novoteris, LLC.

Phone 714-705-4576

Email

Read more news from Novoteris.

SOURCE Novoteris, LLC.




Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.